File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study
  • Basic View
  • Metadata View
  • XML View
TitleEffects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study
 
AuthorsLam, DCL1
Lam, B1
Wong, MKY1
Lu, C1
Au, WY1
Tse, EWC1
Leung, AYH1
Kwong, YL1
Liang, RHS1
Lam, WK1
Ip, MSM1
Lie, AKW1
 
KeywordsAzithromycin
Bronchiolitis obliterans syndrome (BOS)
Hematopoietic SCT (HSCT)
 
Issue Date2011
 
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
 
CitationBone Marrow Transplantation, 2011, v. 46 n. 12, p. 1551-1556 [How to Cite?]
DOI: http://dx.doi.org/10.1038/bmt.2011.1
 
AbstractBronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n10) received oral azithromycin 250 mg daily while the control group (n12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV 1). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV 1 measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study. © 2011 Macmillan Publishers Limited.
 
ISSN0268-3369
2012 Impact Factor: 3.541
2012 SCImago Journal Rankings: 1.201
 
DOIhttp://dx.doi.org/10.1038/bmt.2011.1
 
ISI Accession Number IDWOS:000298326500009
Funding AgencyGrant Number
Pfizer Pharmaceuticals
Funding Information:

This study and the drug used in this study were sponsored by Pfizer Pharmaceuticals.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLam, DCL
 
dc.contributor.authorLam, B
 
dc.contributor.authorWong, MKY
 
dc.contributor.authorLu, C
 
dc.contributor.authorAu, WY
 
dc.contributor.authorTse, EWC
 
dc.contributor.authorLeung, AYH
 
dc.contributor.authorKwong, YL
 
dc.contributor.authorLiang, RHS
 
dc.contributor.authorLam, WK
 
dc.contributor.authorIp, MSM
 
dc.contributor.authorLie, AKW
 
dc.date.accessioned2011-09-23T05:50:01Z
 
dc.date.available2011-09-23T05:50:01Z
 
dc.date.issued2011
 
dc.description.abstractBronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n10) received oral azithromycin 250 mg daily while the control group (n12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV 1). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV 1 measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study. © 2011 Macmillan Publishers Limited.
 
dc.description.naturepostprint
 
dc.identifier.citationBone Marrow Transplantation, 2011, v. 46 n. 12, p. 1551-1556 [How to Cite?]
DOI: http://dx.doi.org/10.1038/bmt.2011.1
 
dc.identifier.citeulike8819673
 
dc.identifier.doihttp://dx.doi.org/10.1038/bmt.2011.1
 
dc.identifier.epage1556
 
dc.identifier.hkuros193943
 
dc.identifier.hkuros193942
 
dc.identifier.isiWOS:000298326500009
Funding AgencyGrant Number
Pfizer Pharmaceuticals
Funding Information:

This study and the drug used in this study were sponsored by Pfizer Pharmaceuticals.

 
dc.identifier.issn0268-3369
2012 Impact Factor: 3.541
2012 SCImago Journal Rankings: 1.201
 
dc.identifier.issue12
 
dc.identifier.pmid21317934
 
dc.identifier.scopuseid_2-s2.0-84856096516
 
dc.identifier.spage1551
 
dc.identifier.urihttp://hdl.handle.net/10722/139447
 
dc.identifier.volume46
 
dc.languageeng
 
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofBone Marrow Transplantation
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subjectAzithromycin
 
dc.subjectBronchiolitis obliterans syndrome (BOS)
 
dc.subjectHematopoietic SCT (HSCT)
 
dc.titleEffects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lam, DCL</contributor.author>
<contributor.author>Lam, B</contributor.author>
<contributor.author>Wong, MKY</contributor.author>
<contributor.author>Lu, C</contributor.author>
<contributor.author>Au, WY</contributor.author>
<contributor.author>Tse, EWC</contributor.author>
<contributor.author>Leung, AYH</contributor.author>
<contributor.author>Kwong, YL</contributor.author>
<contributor.author>Liang, RHS</contributor.author>
<contributor.author>Lam, WK</contributor.author>
<contributor.author>Ip, MSM</contributor.author>
<contributor.author>Lie, AKW</contributor.author>
<date.accessioned>2011-09-23T05:50:01Z</date.accessioned>
<date.available>2011-09-23T05:50:01Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Bone Marrow Transplantation, 2011, v. 46 n. 12, p. 1551-1556</identifier.citation>
<identifier.issn>0268-3369</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/139447</identifier.uri>
<description.abstract>Bronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n10) received oral azithromycin 250 mg daily while the control group (n12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV 1). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV 1 measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study. &#169; 2011 Macmillan Publishers Limited.</description.abstract>
<language>eng</language>
<publisher>Nature Publishing Group. The Journal&apos;s web site is located at http://www.nature.com/bmt</publisher>
<relation.ispartof>Bone Marrow Transplantation</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject>Azithromycin</subject>
<subject>Bronchiolitis obliterans syndrome (BOS)</subject>
<subject>Hematopoietic SCT (HSCT)</subject>
<title>Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study</title>
<type>Article</type>
<description.nature>postprint</description.nature>
<identifier.doi>10.1038/bmt.2011.1</identifier.doi>
<identifier.pmid>21317934</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84856096516</identifier.scopus>
<identifier.hkuros>193943</identifier.hkuros>
<identifier.hkuros>193942</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84856096516&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>46</identifier.volume>
<identifier.issue>12</identifier.issue>
<identifier.spage>1551</identifier.spage>
<identifier.epage>1556</identifier.epage>
<identifier.isi>WOS:000298326500009</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>8819673</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/139447/1/Content.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong